

#### **Project Title**

Sustainability Phase: Inhaled Corticosteroids for All Asthma During COVID-19 Pandemic

#### **Project Lead and Members**

P.H. Pang, T Lee, J.S. Ang, A.R.Y. Tan, S.Y. Lee, L. Prabhakaran

#### **Organisation(s)** Involved

Tan Tock Seng Hospital

#### Healthcare Family Group(s) Involved in this Project

Medical, Nursing, Pharmacy

#### **Applicable Specialty or Discipline**

Respiratory & Critical Care Medicine, Emergency Medicine

#### **Project Period**

Start date: Jan 2019

Completed date: Mar 2022

#### Aims

To sustain the prescription of inhaled corticosteroids (ICS) in asthma patients discharged from Emergency Department above 92% following our Clinical Practice Improvement Project (CPIP)

#### Background

See poster attached/below

#### Methods

See poster attached/below



#### Results

See poster attached/ below

#### **Lessons Learnt**

Not available

#### Conclusion

See poster attached/below

#### **Additional Information**

Accorded the NHG Quality Day 2022 (Category A: Improving and Sustaining Quality & Safety) Merit Award

#### **Project Category**

Care & Process Redesign

Productivity, Cost Saving, Quality Improvement, Clinical Practice Improvement

#### Keywords

Asthma, Appropriate Treatment

#### Name and Email of Project Contact Person(s)

Name: Dr Esther Pang Pee Hwee

Email: pee\_hwee\_pang@ttsh.com.sg



# Sustainability Phase: Inhaled Corticosteroids for All Asthma During COVID-19 Pandemic



Adding years of healthy life

## P H Pang<sup>1</sup>, T Lee<sup>2</sup>, J S Ang<sup>3</sup>, A R Y Tan<sup>2</sup>, S Y Lee<sup>4</sup>, L Prabhakaran<sup>4</sup> <sup>1</sup>Department of Respiratory & Critical Care Medicine (RCCM),

<sup>2</sup>Division of Pharmacy, <sup>3</sup>Department of Emergency Medicine, <sup>4</sup>Division of Nursing

### **Mission Statement**

To sustain the prescription of inhaled corticosteroids (ICS) in asthma patients discharged from Emergency Department above 92% following our CPIP

Team Members													
	Name	Designation	Department										
Team	Dr Esther Pang Pee Hwee	Consultant	RCCM										
Leaders	Mr Lee Tingfeng	Senior Pharmacist	Pharmacy										
Team	Dr Ang Joo Siang	Consultant	<b>Emergency Medicine</b>										
Members	Ms Tan Rui Yi Alyssa	Senior Pharmacist	Pharmacy										
	Ms Lathy Prabhakaran	Senior Nurse Clinician	Nursing										
	Ms Lee Shu Yi	Senior Staff Nurse	Nursing										
Sponsors	A/Prof Abisheganaden John Arputhan	Head	RCCM										
	Adj Asst Prof Ang Hou	Head	Emergency Medicine										
Facilitator													

#### Causes of ICS Not Prescribed for Lack of knowledge on latest GINA guidelines and Asthma Patients Upon ED Discharge umulative **Cause A** Votes rationale of ICS ED Pharmacy did not clarify with prescribing doctor Cause B **Cause C** No documentation in prescription's instruction column Patients' lack of knowledge on asthma treatment **Cause D** 40 ED did not trigger asthma nurse review Cause E 20 No communication btw asthma nurse and ED doctor **Cause F** Cause A Cause B Cause C Cause D Cause E Cause

**Pareto Chart** 

### Implementation


### **Evidence for a Problem Worth Solving**


Short-acting beta agonist (SABA) has been first-line treatment for asthma for many years. Patients often do not see the need for regular inhaled corticosteroids (ICS). Since 2019, Global Initiative for Asthma (GINA) no longer recommends treating asthmatic adults with SABA only. All patients should receive ICS to reduce the risk of severe exacerbations. A local audit (2011-2015) showed that almost 1/3 of those admitted for severe life threatening asthma exacerbations were only on SABA. The prescription of ICS in asthma patients discharged from Emergency Department of TTSH was a median of only 79.3% from January to May 2019. Our TTSH data paled in comparison to NUH's data which showed a median of 100% ICS prescription for the year 2017.

Root Cause	Intervention	Implementation Date
Cause B: ED Pharmacy did not clarify with prescribing doctor	ED pharmacy intervention	23 May 2019
Cause A: Lack of knowledge on latest GINA guidelines and rationale of ICS Cause C: No documentation in	Updates in Asthma for the ED physicians	26 July 2019 25 March 2022
prescription's instruction column Cause D: Patients' lack of knowledge on asthma treatment	Asthma Educational Videos	11 November 2020 13 January 2022
Re	sults	

Sustainability Phase: Runchart on Prescription of Inhaled Corticosteroids (ICS)


in Asthma Patients Discharged from ED Period: Jan 2019 to Feb 2022





ICS prescription (%) — Median

### **Flow Chart of Process**



Inhaled Pre	40% 30%	<u>26/7/19</u>					2:												(.	Jun	<u>11/</u> Lau edu	11/20 Inch of Ication	f patie nal vid	nt eos		,			, .				ation	ınch o al vide	<u>13/1/</u> f patie o "Wh Asthr	ent nat	Asthr	ites in ma	
	20% 10%	_	ا discip	Multi- linary eting	PDSA Pharr	1. 20	•	ites in <i>l</i> ne ED p														tec	inhale hnique ıTube 	es on T	TSH									At	tack?"	on TT chani	SH	for th physi	
	0%			•	+		<b>V</b>																•						1	1							¥		+
		Jan-19	Feb	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan-20	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan-21	Feb	Mar	Apr	Мау	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Jan-22	Feb	Mar
												-	<b>-</b> IC	S Pr	rescr	ripti	on (	%)		Targ	et	_	Med	dian															

	Jan- 19	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan- 20	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan- 21	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Jan- 22	Feb
No. of Inhaled Corticosteroids Prescribed	65	53	51	54	55	56	47	49	45	50	66	63	63	50	39	23	22	15	24	18	22	31	28	31	30	18	14	33	7	9	24	24	19	16	14	18	23	33
ED asthma discharges	82	68	70	62	63	59	49	49	47	52	68	64	65	52	41	23	22	16	27	19	26	34	30	33	35	21	14	36	7	10	26	26	21	16	16	20	24	35

### **Cost Savings**

- Number of ward bed days saved as a result of prevented hospital admissions for asthma over a 12-month period ranged from 93.6 to 148.8 days.
- Estimated cost savings from prevented hospital admissions for asthma over a 12-month period ranged from \$28,128 to \$37,440.
- Estimated cost savings from prevented reattendances at Emergency Department for asthma over a 3-month period ranged from \$896 to \$1,536.

### **Problems Encountered**

- Prescribing ICS for all asthmatic patients is a paradigm shifting practice. Many physicians were still prescribing SABA monotherapy for asthma.
- Patient reliance on SABA is reinforced by its low cost and rapid relief of asthma symptoms. Patients often do not see the need for regular ICS and continue to rely on SABA for their asthma.
- The COVID-19 pandemic was a difficult period for TTSH with major impact on our number of ED attendances for asthma exacerbations, manpower allocation, and asthma education for both physicians and patients.

### **Strategies to Sustain**

- Regular quarterly feedback of ICS prescription rates to ED pharmacy and ED physicians
- Regular updates in asthma for ED physicians by RCCM
- ED MO orientation pack and Asthma Policy & Procedure
- Asthma nurse clinicians to follow up with patients treated and discharged from ED (face to face review or telephonic call)
- Improve patient education asthma discharge advice, videos on coping after an asthma attack and inhaler techniques.